Key result
Lowering the platelet count within the normal range using a thrombopoietin inhibitor reduced experimental occlusive thrombogenesis on collagen-coated vascular grafts in baboons without impairing hemostasis.
Why the study?
Does moderate platelet count reduction by thrombopoietin inhibition reduce experimental occlusive thrombogenesis without impairing hemostasis in baboons?
Population
Baboons (primates)
Design
Preclinical
Authors
Loading...
Hypothesis-generating for moderate platelet reduction as antithrombotic strategy; leaves open translation to human thrombotic disease.
Does moderate platelet count reduction by thrombopoietin inhibition reduce experimental occlusive thrombogenesis without impairing hemostasis in baboons?
Suppressing platelet production to moderately lower platelet counts within the normal range reduces thrombogenesis without impairing hemostasis in primates, offering a potential novel antithrombotic strategy.
Tucker et al. (2010) studied Thrombosis. Thrombopoietin inhibitor was evaluated on Experimental occlusive thrombogenesis on collagen-coated vascular grafts. Lowering the platelet count within the normal range using a thrombopoietin inhibitor reduced experimental occlusive thrombogenesis on collagen-coated vascular grafts in baboons without impairing hemostasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: